Novartis AG, of Basel, Switzerland, is partnering with researchers from the Banner Alzheimer's Institute in a medical trial to determine whether two investigational anti-amyloid drugs – an active immunotherapy and an oral medication – can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.